Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2023 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

TORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing...
February 14, 2023 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to...
February 02, 2023 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and...
January 18, 2023 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and...
January 09, 2023 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and...
January 04, 2023 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. Provides 2023 Corporate Update

Company Plans to Report Phase 1 Interim Analysis for RE104 in Q1 2023 and Include Data Differentiating its Safety, Tolerability and Pharmacodynamic Profile from Other Psychedelics in Clinical...
December 06, 2022 08:00 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for...
November 18, 2022 17:05 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Puts in Place At-The-Market Equity Facility

TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative and...
November 14, 2022 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results

Completed RE104 Phase 1 prespecified dose cohorts and on track to deliver interim Phase 1 analysis in the first calendar quarter of 2023.Appointed Greg Mayes as President and Chief Executive Officer,...
November 07, 2022 07:30 ET | Source: Reunion Neuroscience Inc.

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET

TORONTO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative...